CoChat

Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance

Open access
Brynne, Svanström, Åberg‐Wistedt, Hallén, Bertilsson · 1999 · British Journal of Clinical Pharmacology
Cited by 48

The DOI matches its Crossref record.

Abstract

Aims To investigate the change in disposition of tolterodine during coadministration of the potent cytochrome P450 2D6 (CYP2D6) inhibitor fluoxetine. Methods Thirteen patients received tolterodine l‐tartrate 2 mg twice daily for 2.5 days, followed by fluoxetine 20 mg once daily for 3 weeks and then concomitant administration for an additional 2.5 days. They were characterized as extensive metabolizers (EM1 with one functional CYP2D6 gene, EM2 with two functional genes) or poor metabolizers (PM). Results Nine patients, three EM2 and four EM1 and two PM, completed the trial. Following tolterodine administration, the area under the serum concentration–time curve (AUC) of tolterodine was 4.4‐times and 30‐times higher among EM1 and PM, respectively, compared with EM2. The AUC of the 5‐hydroxymethyl metabolite (5‐HM) was not quantifiable in PM. Fluoxetine significantly decreased (P<0.002) the oral clearance of tolterodine by 93% in EM2 and by 80% in EM1. The AUC of 5‐HM increased in EM2 and decreased in EM1. However, the exposure to the active moiety (unbound tolterodine +5‐HM) was not significantly increased in the two phenotypes. The subdivision of the EM group showed a 2.1‐fold increase in active moiety in EM2 but the exposure was still similar to EM1 compared with before the interaction. Conclusions The study suggests a difference in the pharmacokinetics of tolterodine and its 5‐hydroxymethyl metabolite depending on the number of functional CYP2D6 genes. Fluoxetine significantly inhibited the hydroxylation of tolterodine. Despite the effect on the pharmacokinetics of tolterodine in extensive metabolizers, the clinical effect is expected to be within normal variation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1999.00051.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 48

Metadata

Authors
Brynne, Svanström, Åberg‐Wistedt, Hallén, & Bertilsson
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1999-10
Volume
48
Issue
4
Pages
553-563
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1670451451
Cited by
48
References
0
FWCI
1.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance. https://app.cochat.ai/papers/10.1046/j.1365-2125.1999.00051.x
The paper
Brynne, Svanström, Åberg‐Wistedt, Hallén, & Bertilsson. (1999). Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.1999.00051.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.